In this episode of MedInsights Unleashed, Professor Pierre Gholam, MD., FAASLD, AGAF, returns to explore the transformative potential of GLP1-based therapies beyond diabetes and obesity. The discussion highlights how these drugs may play a groundbreaking role in **cancer prevention—particularly liver cancer—**by addressing the root causes of metabolic dysfunction, a growing public health crisis affecting millions of Americans. Prof. Gholam emphasizes the need for multidisciplinary collaboration among hepatologists, endocrinologists, and primary care providers to improve early detection and treatment of fatty liver disease through noninvasive diagnostics and proactive referral pathways. The episode also looks ahead to emerging oral and multi-agonist GLP1 therapies, marking a new frontier in personalized metabolic and oncologic care.